Homepage

Read about the Oxford Vaccine Centre’s COVID-19 vaccine trial.

Com-COV2: Alternating vaccines trial expands to include two additional vaccines –find your closest study site and read the press release

NHS Parliamentary Awards; The Excellence in Healthcare Award Winner: Oxford Vaccine Group and Jenner Institute

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

OVG's director recognised in Queen’s Birthday Honours

Andrew Pollard, Director of the Oxford Vaccine Group, and Professor of Paediatric Infection and Immunity, becomes a Knight Bachelor for services to Public Health, particularly during the COVID-19 Pandemic.

First trial participants vaccinated with Oxford COVID-19 variant vaccine

The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.

Book cover of "Brain fever" and a portrait of R. Moxon

New book highlights life-saving role vaccines play in prevention of killer diseases

'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.

Oxford researchers identify levels of antibody protection required to prevent symptomatic COVID-19

Researchers from the University of Oxford have today released their findings about the so-called ‘correlates of protection’ against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.

Mockup of two doses of a COVID-19 vaccine with needle

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.

Take part in a clinical trial – see a list of all the trials we are currently recruiting to.

Child being vaccinated

Non-COVID research statement

The Oxford Vaccine Group will be continuing with some of our non-COVID research, particularly our paediatric studies, during the COVID-19 pandemic. This is because as part of these studies we give babies their routine primary immunisations on behalf of their GPs. This reduces the administrative burden on the NHS, allowing them to free up capacity and prioritise their workload to be focused on doing what is necessary to manage the response to the COVID-19 pandemic. The participants also benefit from having the vaccines in the safety of their homes or a convenient location.

Vaccine Knowledge

The Vaccine Knowledge Project aims to be a source of independent information about vaccines and infectious diseases.

See more

Research

Vaccines are a key component of global health policy and are essential in the defence of the health of young children. Our research focuses on the development and evaluation of new and improved vaccines.

Explore

Events and Training

We are committed to providing high quality education and training, together with research updates for medical professionals and all those involved in the area of vaccines and paediatric and adult infectious diseases.

Learn

Get involved

There are a number of ways in which you can get involved in our research, inform our research and find out more about our work. To find out more about any of these options, follow the link below.

Participate

Latest publications

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil; an exploratory analysis of a randomised controlled trial
Journal article

Clemens SC. et al, (2021)
"Should children be offered covid-19 vaccination?" No
Journal article

Wilkinson D. et al, (2021), BMJ: British Medical Journal
Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)
Journal article

Flaxman A. et al, (2021), SSRN Electronic Journal
Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine
Journal article

Liu X. et al, (2021), SSRN Electronic Journal
A Salmonella Typhi Controlled Human Infection Study for Assessing Correlation between Bactericidal Antibodies and Protection against Infection Induced by Typhoid Vaccination.
Journal article

Jones E. et al, (2021), Microorganisms, 9

Upcoming events

Virtual Influenza Update Training

Wednesday, 22 September 2021, 10am to 12.30pm

This training is for general practice nurses and other health professionals who as part of their role already administer and promote / advise about influenza vaccines. The training will cover the theory of the influenza programme. ** Please note the local logistics of delivering the 2021/22 influenza programme will NOT be addressed **

Online Introduction to Immunisation Training - 6 October 2021

Wednesday, 06 October 2021, 9.15am to 3pm

This training is for general practice nurses and other health professionals who are new to the role of administering and promoting and / or advising about vaccines.

Oxford Vaccine Group 17th Immunisation Seminar

Thursday, 17 March 2022, 9am to 4pm @ Kassam Conference & Events Centre, Grenoble Rd, Littlemore, Oxford OX4 4XP

Save the date!

We’ve made a vaccine, now you can make the difference

We’ve heard about how effective vaccines are, but what do we need for them to have the biggest impact on the coronavirus pandemic?

How does herd immunity work?

‘Herd immunity’ or 'herd protection' gives protection to vulnerable people such as newborn babies, elderly people and those who are too sick to be vaccinated.

How to make a vaccine in record time

Vaccines usually take decades to develop – so how is Oxford University's ChAdOx1 nCoV-1 vaccine trial moving so quickly? It comes down to careful planning, extraordinary logistics and a whole lot of help from partners around the world.